

PICO-TESLA

MAGNETIC THERAPIES, LLC

News Release

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

Pico-Tesla reports first seven patients enrolled in IRB-approved pilot study for treating *type 2 diabetes* with its proprietary magnetic (*Magneceutical™*) therapy

Precursor open-label study showed *Magneceutical™* therapy produced "clinically significant reductions" in mean *A1c* levels of seven patients with type 2 diabetes

Published animal data¹ offers evidence that "...electromagnetic fields may have relevant effects in mammals, affecting parameters like...blood glucose..."

Company will present at 'OneMedForum 2010' finance conference in San Francisco, January 12-14

LITTLETON, Colo., Dec. 17, 2009 -[Pico-Tesla, The *Magneceutical™* Therapy Company](#), announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled **Pilot Study** of persons who have **type 2 diabetes**, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company's patented **Resonator™** system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin *A1c* levels. **For more information about this Pilot Study, call Pico-Tesla at 303-795-3222.**

In an Open-Label Study that was the stimulus for the Pilot Study, 10 patients with type 2 diabetes were given three treatments per week with *Magneceutical™* therapy for a total of 13 weeks. Seven (7) of these patients were taking prescription oral medications to manage their type 2 diabetes, and three patients were not. The mean *A1c* levels of the seven patients who were taking prescription oral medications while receiving *Magneceutical™* therapy were reduced by a "clinically significant" amount at the end of the 13-week study, while the mean *A1c* levels of the three patients who were not on drug therapy were not reduced.

The protocols for the Open-Label Study and the current Pilot Study were developed in consultation with **Michael McDermott, M.D.**, Director, Endocrinology and Diabetes Practice, University of Colorado Hospital, Aurora, Colo.; and with **Mitchell Gershten, M.D.**, an internist and staff physician at Saint Mary's Hospital in Grand Junction, Colo.

"The subjects of the Pilot Study are being treated with our Resonator system three times a week for 13 weeks at approximately 90 minutes per treatment," said **Allen Braswell**, president and CEO of Pico-Tesla. "The primary outcome of this Pilot Study will be measurement of improvement in the subjects' hemoglobin *A1c* level after 13 weeks of treatment compared to baseline. For people without diabetes, the normal range for the hemoglobin *A1c* test is between 4% and 6%. The higher the hemoglobin *A1c*, the higher the risks of developing complications related to diabetes," said Braswell.

Allen Braswell will be presenting the Pico-Tesla story to investors at next month's "OneMedForum 2010" finance conference in San Francisco, Jan. 12-14, at the Sir Francis Drake Hotel.

Diabetes mellitus type 2 or **type 2 diabetes** (formerly called **adult-onset diabetes**), a disorder characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency, is often initially managed by increasing exercise and dietary modification; prescription medications are typically needed as the disease progresses. There are nearly 24 million people in the U.S. (almost 8% of the population) with diabetes, with about 18 million being diagnosed-90% of whom are Type 2. With prevalence rates doubling between 1990 and 2005, CDC has characterized the increase as an *epidemic*.

Magneceutical[™] Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device-the *Resonator*[™], invented by **Dr. Jerry I. Jacobson**, along with **proprietary therapeutic protocols**-intended to improve a number of the signs and symptoms of Parkinson's and other diseases, including Type 2 Diabetes.

An animal study-published in the April 1, 2008, issue of *BioMagnetic Research and Technology*-concluded: "The evidence suggests that long term exposure to electromagnetic fields with a well-defined frequency may have relevant effects on parameters such as body weight, blood glucose and fatty acid metabolism."

Privately held [Pico-Tesla Magnetic Therapies](#) is an emerging medical technology company based in Littleton, Colo.

CAUTION: The Resonator[™] device is an Investigational Device limited by federal (or United States) law to investigational use. The Resonator[™] device is not for sale, nor is the *Magneceutical*[™] Therapy generally available outside of Investigational Review Board (IRB)-approved clinical studies.

1 "Effects of electromagnetic fields of low frequency and low intensity on rat metabolism," *BioMagnetic Research and Technology* 2008, 6:3, Gerardi, et al

#####